Format

Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2000 Nov 9;343(19):1350-4.

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.

Author information

1
Division of Cancer Biology, Johns Hopkins Oncology Center, Baltimore, MD 21231, USA.

Erratum in

  • N Engl J Med 2000 Dec 7;343(23):1740.

Abstract

BACKGROUND:

The DNA-repair enzyme O6-methylguanine-DNA methyltransferase (MGMT) inhibits the killing of tumor cells by alkylating agents. MGMT activity is controlled by a promoter; methylation of the promoter silences the gene in cancer, and the cells no longer produce MGMT. We examined gliomas to determine whether methylation of the MGMT promoter is related to the responsiveness of the tumor to alkylating agents.

METHODS:

We analyzed the MGMT promoter in tumor DNA by a methylation-specific polymerase-chain-reaction assay. The gliomas were obtained from patients who had been treated with carmustine (1,3-bis(2-chloroethyl)-1-nitrosourea, or BCNU). The molecular data were correlated with the clinical outcome.

RESULTS:

The MGMT promoter was methylated in gliomas from 19 of 47 patients (40 percent). This finding was associated with regression of the tumor and prolonged overall and disease-free survival. It was an independent and stronger prognostic factor than age, stage, tumor grade, or performance status.

CONCLUSIONS:

Methylation of the MGMT promoter in gliomas is a useful predictor of the responsiveness of the tumors to alkylating agents.

PMID:
11070098
DOI:
10.1056/NEJM200011093431901
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center